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  Correlates of immune-mediated protection to most viral and cancer vaccines are still un-
known. This impedes the development of novel vaccines to incurable diseases such as HIV and 
cancer. In this study, we have used functional genomics and polychromatic fl  ow cytometry to 
defi  ne the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in 
a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immuniza-
tion with YF17D leads to an integrated immune response that includes several effector arms 
of innate immunity, including complement, the infl  ammasome, and interferons, as well as 
adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell 
response. Development of these responses is preceded, as demonstrated in three independent 
vaccination trials and in a novel in vitro system of primary immune responses (modular 
immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts 
for specifi  c transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the 
different effector arms of the immune response. These results clearly show that the immune 
response to a strong vaccine is preceded by coordinated induction of master transcription 
factors that lead to the development of a broad, polyfunctional, and persistent immune 
response that integrates all effector cells of the immune system. 
© 2008 Gaucher et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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immune in vitro construct [MIMIC] co-culture system), to 
identify the emerging protective immune response induced 
in humans by vaccination with YF17D, in an eff  ort to un-
ravel the correlates of protection conferred by one of the 
most potent vaccines ever generated. 
    RESULTS   
  Vaccination with YF17D rapidly and transiently induces 
modulation of genes associated with multiple pathways 
  RNA samples obtained from whole blood of 15 YF17D-vac-
cinated individuals (from the Montreal cohort) on the day of 
vaccination (day 0) and at several time points after vaccina-
tion (day 3, 7, 10, 14, 28, and 60) were amplifi  ed and hybrid-
ized onto Illumina chips and analyzed. Expression profi  les of 
594 genes (Supplemental document 1, available at http://
www.jem.org/cgi/content/full/jem.20082292/DC1) were 
found to change signifi  cantly between day 0 and any time 
point after vaccination (with P   <   0.05 and fold change less 
than     1.3 or   >  1.3). The peak of modulation of gene expres-
sion, as shown by heat map representation (  Fig. 1 a  ) and prin-
cipal component analysis (  Fig. 1 b  ), primarily occurred at 
days 3 and 7 after vaccination, whereas a limited number of 
signifi  cant genes were modulated in response to vaccination 
at day 10 after vaccination or beyond.   
  Independent component analysis (ICA), followed by 
gene set enrichment, identifi  ed transcription factors with pre-
dicted (  11  ) target genes showing a specifi  c modulation after 
YF17D vaccination (  Fig. 2   and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20082292/DC1).   With 
this approach, three major nodes of transcriptional regulation 
        Correlates of immune-mediated protection to most viral and 
cancer vaccines are still unknown. Moreover, there is a paucity 
of information regarding the qualitative and quantitative prop-
erties of emerging protective responses in vivo in humans, and 
this has been a major impediment to vaccine development (  1  ). 
Although humoral immunity is clearly the dominant correlate 
of protection for vaccines against bacterial pathogens (  2  ), vi-
ruses or tumors require a more complex immune response 
with contributions from both T and B cells (  3  ). Innate immu-
nity, which is known to shape the development of adaptive 
immune responses, could also contribute to vaccine-mediated 
protection through mechanisms yet to be defi  ned. 
  Developed empirically in the 1930s, the live attenuated 
yellow fever (YF) vaccine 17D (YF17D) is considered one of 
the most successful vaccines ever made (  4  ); a single dose can 
confer protective immunity for up to 35 yr, in almost all vac-
cinated individuals. The humoral immune response to 17D is 
generally considered the main mediator of protection against a 
challenge infection with wild-type YF virus. Passive immuni-
zation in monkeys (  5  ) and mice (  6  ) has mediated protection 
against YF infection. Although the humoral response inargu-
ably plays a central role, we cannot rule out the contribution 
of the other arms of the immune system, cellular and innate 
immunity, as help from CD4  +   T cells is needed to generate a 
strong B cell response. With the disease being caused by a vi-
rus, and the vaccine itself being an attenuated virus, one could 
expect cytotoxic T cells to play a crucial role in destroying vi-
rally infected cells, and thus preventing viral replication and 
spreading. Surprisingly, there is very little published data on 
the cellular response to the YF17D vaccine in humans. The 
kinetics of the levels of total CD4  +   and CD8  +   T cells (  7  ) and 
nonspecifi  c memory CD4  +   and CD8  +   T cells (  8  ) after vacci-
nation were initially studied, and the fi  rst study of YF17D 
antigen-specifi  c T cells came from Co et al., who mapped a 
series of HLA-B35  –  restricted CD8  +   epitopes to the envelope, 
NS1, NS2b, and NS3 proteins (  9  ). Miller et al. recently de-
scribed the kinetics and properties of the antigen-specifi  c 
CD8  +   T cell memory response after YF17D vaccination (  10  ). 
  The identifi  cation of correlates of protection to YF, how-
ever useful it will be, is destined to be diffi   cult. Classical stud-
ies where vaccinated subjects are challenged with a virulent, 
wild-type strain can obviously not be performed on humans. 
Therefore, we have to rely on data derived from vaccination 
campaigns performed in populations living in endemic areas 
or among high-risk people. Furthermore, the vaccine  ’  s high 
effi     cacy makes it nearly impossible to identify individuals 
who did not acquire protective immunity from it, and it is 
virtually impossible to study such subjects. For these reasons, 
we have to develop and rely on other parameters that can in-
dicate the strength of the immune response induced in the 
vaccinated individuals, such as the level of viremia, the neu-
tralizing antibody titers, or the breadth of the cellular im-
mune response. 
  Herein, we have used a systems biology approach com-
bined with multiparametric fl  ow cytometry and a novel in vi-
tro system of primary immune responses (VaxDesign  ’  s modular 
    Figure 1.         Vaccination with YF17D induces early gene modulation.  
Global view of gene modulation in total blood cells after YF17D vaccina-
tion, as analyzed by gene array on the Montreal cohort (  n   =  9 – 15, 
depending on the time point). Heat map representation (a) and PCA 
(b) using the signifi  cantly modulated genes, in at least one comparison 
versus day 0.     JEM VOL. 205, December 22, 2008 
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Genes associated with B cell activation (BANK1, CD19, IGJ, 
TNFRSF13B, and TNFRSF17l;   Fig. 3 e  ) were also modu-
lated. Other genes also involved in the induction of an 
immune response, such as TAP1 and TAP2, which encode pro-
teins involved in antigen processing and presentation (  12, 13  ), 
and SOCS1, which encodes a protein involved in a negative 
feedback loop meant to attenuate cytokine signaling (  14  ), were 
up-regulated as well (Supplemental document 1). Strikingly, 
we observed that 43 genes encoding ribosomal proteins were 
down-regulated in PBMCs early after vaccination with YF17D 
(Supplemental document 1), confi  rming the fi  ndings of a previ-
ous study (  15  ). Collectively, these results reveal that vaccina-
tion with YF17D stimulated a rapid and transient modulation 
of several genes of immunological importance, which al-
lowed us to infer a signature of gene modulation by ICA. 
  Two levels of validation were performed to confi  rm the 
results observed in this initial trial; the fi  rst validation was 
achieved by performing quantitative real-time PCR (qPCR) 
on RNA from 7 volunteers from the Montreal cohort for 
43 genes selected to represent 8 of the identifi  ed transcrip-
tion nodes and some of their target genes. As shown in 
Fig. S2 (available at http://www.jem.org/cgi/content/full/
jem.20082292/DC1), we could observe a highly signifi  cant 
correlation between the results obtained by qPCR and those 
of downstream target genes were found as early as day 3 (IRF7 
and STAT1) and day 7 (ETS2). Other nodes of transcription 
factors (IRF1, IRF8, GATA6, GATA1, TAL1, FOXO3a, 
E2F4, E2F1, LMO2, SRF, and CEBPB) also controlled the 
expression of several of the genes and pathways that were 
modulated in the fi  rst week after immunization. 
  Many of the genes that were modulated by YF17D vac-
cination could be classifi  ed under diff  erent functional catego-
ries, based on published literature (  Fig. 3   and Supplemental 
document 2, available at http://www.jem.org/cgi/content/
full/jem.20082292/DC1).   Some Toll-like receptor (TLR)  –
  associated genes (TLR7, MYD88, and IRF7) were also up-
regulated, leading to the activation of the IFN pathway, as 
monitored by the induction of several IFN-induced genes 
(IFI27, IFI30, G1P2, G1P3, and OAS1-3;   Fig. 3 a   and Sup-
plemental document 1). Components of the complement 
system (C1QA, C1QB, C3AR1, and SERPING1) were 
found to be up-regulated in blood cells early after vaccination 
(  Fig. 3 b  ). A few macrophage/DC-associated genes were in-
duced signifi  cantly by the vaccine, including CD86 (a marker 
of DC maturation), CSF1R, MARCO, and IFI16, which are 
expressed by cells of the monocyte-macrophage lineage 
(  Fig. 3 c  ). NK cell  –  associated genes (KIR2DL3, KIR2DL4, 
PRF1, GNLY, and GZMB) were also up-regulated (  Fig. 3 d  ). 
    Figure 2.         Transcriptional network of differentially expressed genes after YF17D vaccination, as inferred by gene set enrichment.   Network 
representation of inferred transcription factors (  11  ) and predicted target genes that are signifi  cantly modulated. Node colors indicate fold change of gene 
expression between day 0 and 7 in   n   = 11 volunteers. Rectangular nodes indicate transcription factors identifi  ed by gene enrichment; the different shapes 
indicate genes in the different functional categories of   Fig. 3 (a  –  e)  . Genes that were subsequently evaluated by RT-PCR are identifi  ed by an asterisk. IRF1, 
IRF8, and genes targeted by IRF1 or IRF8, but no other transcription factors in the fi  gure were removed to increase readability (see Fig. S1 for a complete 
map). Fig. S1 is available at http://www.jem.org/cgi/content/full/jem.20082292/DC1.     3122 IMMUNE RESPONSE TO THE YELLOW FEVER VACCINE 17D   | Gaucher et al. 
vation of the infl  ammasome by the vaccine, we quantifi  ed 
the secretion of IL-1    , which has been shown to be processed 
and produced by an active infl  ammasome assembly (  16  ). The 
results show that DCs incubated with live or UV-inactivated 
YF17D showed a marked increased IL-1     secretion (up to 
ninefold, compared with DCs incubated in medium alone), 
whereas heat-inactivated YF17D only triggered a modest 
secretion of the proinfl  ammatory cytokine (  Fig. 5 b   and 
Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20082292/DC1). These functional results confi  rm the 
gene array data, suggesting that YF17D activates components 
of the infl  ammasome complex, and that viral replication is not 
required for this eff  ect. 
  YF17D vaccination leads to the proliferation and expansion 
of several leukocyte subtypes 
  Given that immunization with YF17D gives rise to the up-
regulation of genes associated with diff  erent leukocyte popu-
lations, we were interested in determining whether the vaccine 
also induces the proliferation of these cells. To do so, PBMCs 
from 6 volunteers, sampled at day 0, 3, 7, 10, 14, and 28 after 
vaccination, were stained with anti-Ki67and other specifi  c 
antibodies to identify, by fl  ow cytometry, diff  erent cell sub-
sets that are actively proliferating. The staining/gating strate-
gies and the results are shown in Fig. S5 (a and b, available at 
http://www.jem.org/cgi/content/full/jem.20082292/DC1), 
respectively. An increase in frequencies of Ki67  +   cells in the 
CD4  +  CD8        (2.3-fold increase; P = 0.0049) and the CD4      
CD8  +   (4.7-fold increase; P = 0.0157) populations occurred 
within the fi  rst 14 d after YF17D vaccination, and then de-
creased to insignifi  cant levels. The Ki67  +   NK cell population 
obtained by gene microarray, with coeffi   cients of correlation 
ranging between 0.78 and 0.96. A detailed analysis of the 
entire set of genes is represented in Table S1. The second 
validation was achieved by comparing the aforementioned 
qPCR dataset for the Montreal cohort to datasets from two 
other, independent YF17D vaccination trials: the Lausanne 
cohort (13 volunteers) and the Emory cohort (10 volunteers). 
The results illustrated in   Fig. 4   and in Fig. S3 indicate that 
most genes that were up-regulated in the Montreal cohort 
also showed increased expression in the two other indepen-
dent trials.   Conversely, most down-regulated genes in the 
Montreal cohort also showed decreased levels of expression 
in the samples obtained from the two other trials. These re-
sults demonstrate the proper validation of our gene array data 
by two diff  erent strategies: the use of qPCR and an increase 
in sample size. 
  The YF17D vaccine up-regulates IL-1     production 
  Our gene array results showed that two components of the 
infl  ammasome, caspase-1 and -5, were up-regulated at the 
mRNA level in the Montreal cohort, 3 d after vaccination 
with YF17D (  Fig. 5 a  ).   Two other genes related to IL-1     
production and signaling that were modulated by the vaccine 
are IL-1R2 and -1RN. All of these genes, except for caspase-5, 
were also similarly modulated in the Lausanne cohort. To 
functionally validate the microarray data suggesting the acti-
    Figure 3.         YF17D vaccination stimulates multiple arms of the in-
nate and adaptive immunity.   (a  –  e) Heat map representation of signifi  -
cantly modulated genes, P values listed with each gene indicate the 
largest (least signifi  cant) P value among the signifi  cant fold changes.   n   = 
9  –  15, depending on the time point. The listed genes fall under different 
functional categories: IFN-induced and TLR-associated genes (a); comple-
ment-associated genes (b); macrophage-associated genes (c); NK cell  –
  associated genes (d); and B cell  –  associated genes (e). Supplemental 
document 2 includes a justifi  cation for the attribution of each gene into 
its respective group. Supplemental document 2 is available at http://www
.jem.org/cgi/content/full/jem.20082292/DC1.   
    Figure 4.         Heat map of fold change gene expression between day 0 
and 7, as measured by qPCR.   For a complete heat map of all mea  sured 
fold changes see Fig. S3. Fig. S3 is available at http://www.jem.org/cgi/
content/full/jem.20082292/DC1.   JEM VOL. 205, December 22, 2008 
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most, if not all, of the peptide pools (  >  20), whereas weak re-
sponders (YF005, 011, and 017) recognized only a few (  <  5). 
The CD8  +   responses were generally much weaker than those 
observed in CD4  +   T cells, and although only 2 responders 
recognized 19 of the pools (YF001 and 020), 10 of them rec-
ognized   <  5. Notably, some peptide pools were recognized by 
more volunteers than others (pools 1, 3, and 17 were recog-
nized by CD4  +   T cells of at least 12 volunteers), whereas others 
were recognized by just a few volunteers (pools 5 and 7 were 
recognized by CD4  +   cells of at most 7 volunteers). Both CD4  +   
and CD8  +   T cell peptide-specifi  c responses were persistent, as 
memory proliferative responses to the most immunodominant 
peptide pools were detected as long as 1 yr after immunization 
(unpublished data). These results show that the breadth of the 
T cell responses to the YF17D vaccine is highly variable from 
one vaccinated individual to another, but that those responses 
are persistent. 
  The YF17D vaccine induces a mixed Th1/Th2 response 
that appears early and is persistent 
  Next, we sought to determine at the protein level the cy-
tokine profi  les produced by PBMCs after stimulation with 
YF17D-derived peptide pools. We used cytometric bead 
assay (CBA) to assess the levels of the Th1 cytokines IL-2, 
IFN-    , and TNF, and the Th2 cytokines IL-4 and -10 se-
creted by these cells.   Fig. 6   shows the results for six selected 
volunteers (heat maps); a summary of the CBA results for all 
volunteers and pools tested can be found in Fig. S6 e. In our 
system, high levels of TNF were detected in several superna-
tants, whereas the other cytokines were either found in low 
amounts or not detected. Hence, the qualitative and quanti-
tative features of cytokine production were highly variable; 
pool 3 stimulated a mixed Th1/Th2 response in volunteer 
YF001, but triggered only a Th1 response in subjects YF002, 
3, 9, and 20, whereas no detectable response to this pool 
could be seen in YF019. In most volunteers (12 out of 15), 
both Th1 and Th2 cytokine secretion profi  les were induced 
by YF17D peptide pools. Three volunteers (YF0014, 15, and 
16), who were weak responders to the vaccine as measured 
by T cell proliferation, did not show a mixed Th1/Th2 pro-
fi  le; however, these individuals were still able to mount very 
good antibody responses (Table S2, available at http://www
.jem.org/cgi/content/full/jem.20082292/DC1). 
  We further demonstrated the emergence of a mixed Th1/
Th2 response to the vaccine at the single-cell level using 
polychromatic fl  ow cytometry. First, we confi  rmed the Th1 
phenotype of antigen-specifi  c CD4  +   T cells by stimulating 
PBMCs from vaccinated volunteers (28 d after vaccination) 
with immunostimulatory peptide pools, and identifying anti-
gen-specifi  c T cells by the expression of the activation marker 
CD154 (  17, 18  ) and the production of IL-2 and IFN-    . As 
illustrated in   Fig. 7 a  , 35.2% of CD4  +  CD154  +   cells expressed 
IL-2 alone, 8.6% expressed IFN-     alone, and 29.5% ex-
pressed both IL-2 and IFN-    .   
  To determine if this mixed Th1/Th2 response was per-
sistent, we detected YF17D-specifi  c Th1 and Th2 cells in 
(CD3       CD8  Dim  ; 1.6-fold; P = 0.0474) and non –  T cell PBMCs 
containing monocytes and B cells (CD3       CD4       CD8       ; 1.9-fold; 
P = 0.009) also increased in frequency within the fi  rst 7 d and 
reached insignifi  cant levels thereafter. Altogether, our data 
clearly illustrate that all major cellular subsets of innate and 
adaptive immunity are mobilized during the immune response 
to YF17D. 
  Vaccination with YF17D induces a broad and persistent 
YF-specifi  c T cell response 
  We next assessed the amplitude, breadth, and persistence of 
the YF17D-specifi  c T cell response. PBMCs sampled at day 
60 after vaccination were incubated in the presence of each 
of 22 YF17D-derived peptide pools (Fig. S6 a, available at 
http://www.jem.org/cgi/content/full/jem.20082292/DC1), 
and their proliferation was measured by CFSE labeling. Fig. S6 b 
describes the cytometry gating strategy used, and the results 
are shown in   Fig. 6   (bar graphs) and Fig. S6 (c and d).   Both 
the CD4  +   and CD8  +   T cell proliferative responses were highly 
variable among the vaccinated volunteers. Strong CD4  +   re-
sponders (notably YF001, 002, 009, 018, and 020) recognized 
    Figure 5.         YF17D induces expression of genes associated with 
IL-1     and activates the infl  ammasome.   (a) Heat maps showing 
the up-regulation of genes encoding infl  ammasome components 
and the modulation of other, IL-1      –  associated genes. For IL-1R2 and 
-1RN only probes targeting all transcripts were considered. (b) IL-1    
production by monocyte-derived DCs incubated with live (YF), UV-
inactivated (UV), or heat-inactivated (HI) YF17D, as determined by 
ELISA. NI, noninfected cells. This represents the results from one repre-
sentative of three separate experiments. The results for the two other 
ex  periments are shown in Fig. S4. Fig. S4 is available at http://www.jem
.org/cgi/content/full/jem.20082292/DC1.   3124 IMMUNE RESPONSE TO THE YELLOW FEVER VACCINE 17D   | Gaucher et al. 
tral memory T cells could be detected in all four volunteers 
tested. Together, these results confi  rm the polyfunctionality 
of the immune response induced by YF17D, as we observe 
not only a strong innate immune response but also a mixed 
Th1/Th2 response that is persistent. 
  The transcription factors identifi  ed during in vivo YF17D 
vaccination were also central in an in vitro model of YF17D 
primary immune response 
  The MIMIC system is a powerful tool for the in vitro study of 
the early events taking place in a primary immune response. 
We used this novel approach to validate the multilineage re-
sponse to YF17D, particularly the expression of transcription 
nodes and the secretion of mixed Th1/Th2 cytokines. Blood 
PBMCs sampled at day 365 after vaccination. The cells were 
stimulated for 6 d with YF17D-derived immunostimu-
latory peptide pools to increase the frequency of antigen-
specifi  c cells, and then restimulated with the same pools for 
18 h. The cells were then stained for the activation marker 
CD154, as well as for surface markers, allowing the dis-
crimination between the Th1 (CXCR3  +  CCR4       ) and Th2 
(CXCR3       CCR4  +  CCR6       ) phenotypes in central memory 
T helper cells (  19  ). See Fig. S7 (available at http://www.jem
.org/cgi/content/full/jem.20082292/DC1) for the full stain-
ing and gating strategies and   Fig. 7 b   for the results. Although 
some peptide pools stimulated a mixed Th1/Th2 response 
in a given volunteer, others either stimulated a Th1, a Th2, 
or no particular profi  le. However, both Th1 and Th2 cen-
    Figure 6.         YF17D induces a mixed Th1/Th2 response.   (a) Day 60 PBMCs were stimulated with the 22 peptide pools and assayed by CFSE labeling for 
their proliferative response. Bar graphs show data for six selected volunteers, and the dataset for all the volunteers can be found in Fig. S6 (c and d). At 24 h 
of culture, supernatants were analyzed by CBA to determine the Th1/Th2 cytokine secretion profi  le in response to each pool. The heat maps represent the 
data for the same six volunteers. The Th1/Th2 profi  les determined this way for all the volunteers and pools are shown in Fig. S6 e. Fig. S6 is available at 
http://www.jem.org/cgi/content/full/jem.20082292/DC1.   JEM VOL. 205, December 22, 2008 
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tants were harvested for cytokine quantifi  cation, and the cells 
stained for polychromatic fl  ow cytometry analysis. As shown 
in   Fig. 8 a  , DCs pulsed with YF17D virus (live or UV-inacti-
vated) primed a strong antigen-specifi  c response of naive T 
cells, with up to 4% cells expressing CD154 and IFN-     in 
monocyte-derived DCs from YF-naive individuals were pulsed 
with YF17D virus for 24 h, and then co-cultured for 14 d 
with autologous CD4  +   T cells. The resulting culture superna-
    Figure 7.         YF17D vaccination induces specifi  c CD4+ T cells of 
mixed T helper phenotype.   (a) PBMCs from YF17D-vaccinated volun-
teers (day 28 after vaccination) were stimulated with a group of three 
immunostimulatory YF17D-derived peptides pools, and then stained with 
antibodies against CD4 (surface) and CD154, IL-2, and IFN-g (intracel-
lular). The numbers indicate the percentages of cells within the parent 
population. (b) FACS analysis of PBMCs from day 365 after vaccination. 
Cells from four volunteers were stimulated (S) for with immunostimula-
tory YF17D peptide pools, and then restimulated (RS) or not with the 
same peptide pools before staining. The data were analyzed according to 
the gating strategy shown in Fig. S7, and are expressed as the percentage 
of central memory CD4+ T cells (CD45RA2CCR7+) that express the marker 
for recent activation CD154, and that are either Th1 or Th2 in the RS 
samples, over background (S). Fig. S7 is available at http://www.jem
.org/cgi/content/full/jem.20082292/DC1.   
    Figure 8.         YF17D elicits robust and diverse primary T helper cell 
responses in DC/T cell co-cultures.   (a and b) Purifi  ed T helper cells were 
mixed with DCs that had been incubated with live or UV-inactivated 
YF17D. After 14 d, the cells were harvested and evaluated by fl  ow cytom-
etry for cytokine and CD154 expression after a short restimulation with 
autologous DCs targets that had been left untouched, pulsed with killed 
YF17D, or infected with live YF17D. All data plots show live CD4  + -gated 
events. These are representative data of experiments done on cells from at 
least 10 volunteers. (c) Alternatively, the culture supernatants were har-
vested and evaluated by a multiplex cytokine analysis. Data representative 
of experiments done on cells from two volunteers.     3126 IMMUNE RESPONSE TO THE YELLOW FEVER VACCINE 17D   | Gaucher et al. 
cal processes that are initiated by one of the most potent 
vaccines ever generated, the YF vaccine YF17D, and which 
culminate into persistent immunological memory and long-
term protection against a challenge infection (  20  ). The vac-
cine induced a signifi  cant modulation of 594 genes in whole 
blood cells, with the highest number of genes being induced 
at day 7 after vaccination. ICA and gene set enrichment al-
lowed us to identify several nodes of transcriptional regulation 
that became induced within the fi  rst week after immuniza-
tion. This early response was highly integrated, as several of 
the downstream target genes were coordinately regulated by 
these transcription factors. 
  Of the identifi  ed nodes, IRF7 was prominently involved 
in this masterswitch regulation. The induction of IRF7 has 
been shown to mediate innate and adaptive immunity against 
many viruses, including encephalomyocarditis virus, vesicu-
lar stomatitis virus, infl  uenza virus, and Sindbis virus (  21, 22  ), 
confi  rming the signifi  cance of this gene in mediating protective 
immunity and in inducing strong innate and adaptive im-
mune responses. It was also recently reported that the YF17D 
virus activates DCs by triggering their TLR2, 7, 8, and 9 
(  23  ). Our data reveal that TLR7 and its downstream adaptor 
molecule Myd88 are both up-regulated upon vaccination 
with YF17D. TLR7 is a molecular sensor for single-stranded 
RNA, such as the nucleic acid found in YF17D and other 
fl  aviviruses, and triggering of TLR7 causes the transduction 
of a signal, via Myd88, to up-regulate expression of infl  am-
matory cytokines such as IL-6, IL-12, and TNF (via NF-    B) 
and type I IFNs (via IRF7) (  22, 24  ). Type I IFNs in turn en-
hance the expression of proteins with direct antiviral activity, 
such as ISG20 and OAS1, 2, and 3, which lead to viral RNA 
degradation, and MX1, MX2, ADAR, and EIF2AK2, which 
inhibit viral replication. We are showing that all these genes 
are up-regulated upon YF17D vaccination. 
response to live or UV-inactivated YF17D.   Similarly, YF17D-
pulsed DCs stimulated high numbers of antigen-specifi  c Th2 
cells expressing IL-5 and IL-13, upon restimulation with live 
or inactivated virus (  Fig. 8 b  ). The levels of the cytokines IL-2, 
IFN-    , IL-13, IL-5, and IL-10 in the MIMIC co-culture 
supernatants were measured by multiplex cytokine analysis 
(  Fig. 8 c  ). When YF17D was used as pulse and recall antigen, 
the cells produced high levels of all the cytokines measured ex-
cept IL-10, compared with co-cultures with no recall antigen. 
Collectively, the results show that the MIMIC system induced 
a YF17D-specifi  c primary CD4  +   T cell response, and further-
more, it allowed us to confi  rm the induction of a mixed Th1/
Th2 immune response by the YF17D vaccine. 
  Finally, the MIMIC approach was used to independently 
assess our working hypothesis that the transcriptional nodes in-
duced in whole blood cells after vaccination with YF17D can 
also be induced in vitro by the vaccine. Co-cultures containing 
YF17D-pulsed DCs and CD4  +   T cells (with or without YF17D 
as recall antigen) were harvested and total RNA was isolated 
from the cells. Gene modulation in response to the antigen (day 
7 vs. 0) was assessed by microarray analysis. In total, eight nodes 
of transcriptional regulation of downstream target genes were 
consistently identifi   ed; ETS2, STAT1, IRF1, IRF7, IRF8, 
GATA1, LMO2, and JUN (  Fig. 9  ).   Table S3 (available at 
http://www.jem.org/cgi/content/full/jem.20082292/DC1) 
summarizes the transcriptional nodes identifi  ed with the Mon-
treal cohort, the Lausanne cohort, and the VaxDesign system. 
These data demonstrate that the same central nodes of tran-
scription are activated in in vivo vaccination with YF17D and 
in an in vitro system of primary immune response to the virus. 
    DISCUSSION   
  In this study, we have used systems biology and polychro-
matic fl  ow cytometry to characterize the early immunologi-
    Figure 9.         Consensus transcriptional network of genes differentially expressed on day 7 as compared with day 0  . Network representation of 
inferred transcription factors and predicted target genes that are consistently modulated in at least two out of three datasets, with the third dataset not 
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It is possible that NALP1 infl  ammasomes were not induced in 
volunteers from the Lausanne cohort, whereas NALP3 in-
fl   ammasomes were induced in both cohorts. Interestingly, 
our gene array data also show a modulation of genes that are 
involved in IL-1     signaling, IL-1R2 and IL-1RN. IL-1R2, 
which is a decoy receptor that competes with the binding of 
IL-1     to its receptor (  45  ), is down-regulated, further con-
fi  rming increased infl  ammasome activities and IL-1     process-
ing and secretion after immunization with YF17D. The gene 
encoding IL-1RN, a cytokine that is an IL-1R antagonist, is 
up-regulated upon vaccination; this increase could be part of 
a negative feedback loop or could be caused by the up-regula-
tion of STAT1 and STAT2, two transcription factors that in-
duce IL-1RN up-regulation (  46, 47  ). Activation of the 
infl  ammasome by YF17D was confi  rmed at the protein level 
by incubating immature DCs with the virus and assessing 
their IL-1     secretion. Representative results of ex vivo ex-
periments performed on cells from a minimum of three indi-
viduals are shown in   Fig. 5 b   and Fig. S4, and clearly validate 
the gene expression data, as we could observe a signifi  cant 
up-regulation (up to ninefold) of IL-1    , which is a critical in-
dicator of infl  ammasome formation and activation. Of note, 
we could also observe that the induction of this pathway was 
independent of viral replication, as both UV-inactivated vi-
rus, and to a lesser extent heat-inactivated virus, all induced 
the secretion of IL-1    . As shown in   Fig. 5 a  , the modulation 
of infl  ammasome- and IL-1      –  related genes also similarly oc-
curred in the Lausanne cohort, where increased gene expres-
sion of caspase-1, IL-1RN, and the decrease in the expression 
of IL-1R2, further confi  rmed the activation of the infl  amma-
some after YF17D vaccination. Altogether, these results con-
fi  rm the importance of the infl  ammasome as a target of the 
YF17D vaccine. Whether this pathway is critical for the adju-
vant eff  ect of this vaccine remains to be determined, but is 
certainly suggested by the fact that the infl  ammasome is in-
duced by immunization when alum is used as adjuvant (  43  ). 
Moreover, IL-1     is known to play an important role in the 
regulation of T cell activation at multiple levels, and polymor-
phisms in the IL-1     gene have been linked to smallpox vac-
cine  –  induced fever (  48  ). 
  We observed that YF17D stimulated the up-regulation of 
components of the complement cascade in blood cells, namely 
C1qA and C1qB. These molecules have been shown to induce 
maturation of DCs (  49  ). Furthermore, distinct components of 
the complement pathway were found to be essential in the de-
velopment of humoral and cellular immunity to another fl  a-
vivirus, the West Nile Virus (  50, 51  ). This may underline a 
possible role for the complement system in the establishment 
of immunity in response to YF17D vaccination. 
  The induction of a mixed Th1/Th2 profi  le by YF17D 
was suggested by Querec et al., who reported that the vac-
cine triggers TLR2, 7, 8, and 9 on DCs (  23  ); this was recently 
confi  rmed with in vivo data in humans (  52  ). Our results cor-
roborate these fi  ndings; we have demonstrated at the protein 
level that PBMCs isolated from YF17D-vaccinated volun-
teers display a mixed T helper cell phenotype. Cells from day 
  Another prominent node of transcription regulation in-
duced by YF17D vaccination is the ETS2 transcription fac-
tor. ETS2 is involved in the diff  erentiation and maturation of 
several immune cell types (  25  ). Its expression is up-regulated 
in activated and proliferating T cells (  26  ) and ETS2 is in-
volved in IL-12 p40 (Th1) and IL-5 (Th2) gene expression 
(  27, 28  ). ETS2 obviously plays a key role in the highly inte-
grated response to YF17D, as it enhanced transcription of 
several downstream genes that play critical roles in the matu-
ration and diff  erentiation of T cells, B cells, NK cells, and 
macrophages (  Fig. 2, Fig. 3  , and Fig. S1). Indeed, antigen-
presenting cell  –  specifi  c genes that are targets of ETS2 were 
up-regulated early after vaccination (MARCO, CD86). The 
role of ETS2 in the early induction of innate immunity is 
further demonstrated by the increased expression of NK cell 
receptors, as well as several cytolytic molecules; KIRDL3, 
PRF1, and GZMB are known targets of members of the Ets 
family of transcription factors (  25, 29  ). Moreover, fl  ow cy-
tometry analysis on PBMCs from vaccinated volunteers revealed 
that YF17D stimulates the proliferation of several leukocyte 
populations (Fig. S5 b). 
  Several of the other predicted transcription nodes are 
likely to play signifi  cant roles in the induction of innate and 
adaptive immunity in response to YF17D. IRF1 mediates the 
antiviral activity of IFNs, similar to IRF7 (  30  ). IRF1 and 
IRF8 were found to synergistically activate IL-12 p35 and 
p40 gene expression in macrophages (  31  –  33  ). IRF8 also me-
diates activation of NF-    B upon TLR9 triggering in DCs 
(  34  ), and IRF8 and LMO2 were both found to be expressed 
in B cell germinal centers, suggesting a role in the develop-
ment of the humoral response (  35, 36  ). Moreover, TAL1 may 
be involved in T cell proliferation and diff  erentiation (  37  ). 
E2F4 is involved in cell cycle regulation (  38  ), and FOXO3A 
and E2F1 are mediators of apoptosis (  39, 40  ). 
  A common feature of these masterswitch genes is that they 
control the induction of several pathways of the innate im-
mune response, including type I IFNs, but also the infl  amma-
some and complement. The infl  ammasome is a large protein 
assembly that includes pyrin- and CARD domain  –  containing 
adaptor proteins complexed with cysteine proteinases known 
as caspases. It mediates the processing and activation of these 
caspases, and subsequently the cleavage and secretion of the 
proinfl  ammatory cytokines IL-1     and -18 (  41  ). Activation of 
the infl  ammasome has been recently shown to be induced by 
adenoviruses (  42  ), and to be a key event for the successful ad-
juvant eff  ect of alum, one of the only two adjuvants licensed 
to be used in humans (  43  ). Our gene array results demonstrate 
that two components of the infl  ammasome, caspase-1 and -5, 
were up-regulated after YF17D vaccination, in volunteers 
from the Montreal cohort, whereas only caspase-1 is up-regu-
lated in volunteers from the Lausanne cohort (  Fig. 5 a  ). There 
are diff  erent kinds of infl  ammasomes, each containing a spe-
cifi  c combination of infl  ammatory caspases and adaptor mole-
cules (  44  ). Hence, NALP1 infl   ammasomes contain ASC, 
NALP1, caspase-1, and caspase-5, whereas NALP3 infl  am-
masomes contain ASC, NALP3, and caspase-1 (no caspase-5). 3128 IMMUNE RESPONSE TO THE YELLOW FEVER VACCINE 17D   | Gaucher et al. 
(Table S5, available at http://www.jem.org/cgi/content/full/
jem.20082292/DC1) happens as this innate response pre-
cedes the emergence of YF17D-specifi  c humoral and cellular 
immune responses. Interestingly, complement, IFNs, and the 
infl  ammasome can all impact on the quality of the adaptive 
immune response and trigger Th1/Th2 mixed immune re-
sponses (  42  ). Notably, YF17D triggers TLR2, which is up-
stream of the Th2 pathway (  56  ) and TLR7, 8, and 9, which 
trigger mostly the Th1 pathway (  57  ). Our studies have also 
revealed that the mixed Th1/Th2 CD4  +   response preceded 
B cell responses, as monitored by the detection of antibodies 
in serum of vaccinated subjects and the identifi  cation of gene 
expression signatures specifi  c to B cell responses (Table S2 
and   Fig. 3 e  ). An important outcome of the early develop-
ment of Th2 memory CD4  +   T cells is the generation and 
persistence of a strong antibody response. As for CD8  +   re-
sponses, they could certainly be involved in providing long 
lasting protection against reexposure to the virus. In that con-
text, it will be important to compare the immune response 
described herein to that of individuals that have been reex-
posed to the virus, such as those who live in endemic areas or 
who get reimmunized with the vaccine. 
  The results described herein identify unique features of 
protective immune responses which can now be used as bench-
marks to design and monitor the development of novel vac-
cines. They demonstrate the complexity of this immune 
response and they highlight the fact that it is the sum of all 
arms of the immune response that is most probably required 
for the long-lasting protection induced by this vaccine; and 
they highlight the fact that it is this integrated immune re-
sponse that constitutes the correlates of protection. In that 
context, systems biology becomes an essential tool to identify 
correlates of immune-mediated protection. The recent fail-
ure of the STEP HIV vaccine trial paves the way for the use 
of new immune monitoring strategies focused on the identi-
fi  cation of multilineage and polyfunctional features of candi-
date vaccine-induced immune response. 
    MATERIALS AND METHODS   
  Vaccination of human volunteers and blood collection.     The volun-
teer recruitment and vaccination protocols for this study were approved by 
the research ethics committees of the Centre Hospitalier de l  ’  Universit  é   de 
Montr  é  al (Montreal cohort; 20 volunteers), the Faculty of Biology and 
Medicine of the University of Lausanne (Lausanne cohort; 13 volunteers), 
and Emory University (Emory Cohort; 10 volunteers). Each recruited sub-
ject received a single 0.5-ml subcutaneous injection of the Sanofi  -Pasteur 
17D-204 live-attenuated YF virus vaccine YF-VAX (Montreal and Emory 
cohorts) or Stamaril (Lausanne cohort). For the Montreal cohort, 50 ml of 
blood were drawn from each volunteer in sodium-heparinized Vacutainer 
tubes (BD) on the day of vaccination (day 0) and 3, 7, 10, 14, 28, 60, 90, 
180, and 365 d thereafter. PBMCs were isolated from these samples using 
standard Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation 
and cryopreserved in bovine serum + 10% DMSO in liquid nitrogen. At 
each time point, an additional 10 ml of blood was collected from each vol-
unteer in PaxGene tubes (QIAGEN), for whole-blood RNA isolation. For 
the Lausanne cohort, whole blood was collected in PaxGene tubes at days 0, 
3, and 7 after vaccination. YF17D-specifi  c seroconversion and viremia were 
determined as described in Tables S2 and S5, respectively. 
60 post-vaccination subjects, when stimulated ex vivo with 
YF17D-derived peptides, secreted Th1 and Th2 cytokines in 
their supernatants, as measured by CBA (  Fig. 6   and Fig. S6 e). 
Peptide-stimulated PBMCs from day 28 expressed the Th1 
cytokines IL-2 and/or IFN-    , as revealed by intracellular cy-
tokine staining (  Fig. 7 a  ), and fi  nally, PBMCs from day 365 
after vaccination contained central memory T helper cells 
expressing surface markers typical of Th1 or Th2 cells when 
stimulated twice with immunostimulatory YF17D peptide 
pools (  Fig. 7 b  ). Induction of the Th2 pathway by a vaccine 
is essential for the development of humoral immunity; in that 
context, we noted the induction of several B cell  –  specifi  c 
genes in whole blood from volunteers vaccinated with YF17D, 
including POU2AF1, a transcription factor that is essential 
for mature B cell diff  erentiation (  53  ), and CD19, TN-
FRSF13B (BAFF) and TNFRSF17 (BCMA;   Fig. 3 e  ), which 
are critical for B cell survival, persistence, and isotype switch-
ing (  54  ). This late induction of B cell  –  associated genes (days 
10 and 14) coincided with the onset of YF17D-specifi  c neu-
tralizing antibody production, which occurred by day 14 in 
the majority of the vaccinated volunteers (Table S2). 
  The MIMIC system confi  rmed that the YF17D vaccine 
can induce a mixed Th1/Th2 response, as measured by the 
secretion of the Th1 cytokines IL-2 and IFN-    , and the Th2 
cytokines IL-5 and -13 in the supernatants of the MIMIC 
co-cultures (  Fig. 8 c  ), and by the production of IL-5 and -13 
(  Fig. 8 b  ) or IFN-     (  Fig. 8 a  ) by antigen-specifi  c CD154  +   
T helper cells. The observation that both live and UV-inacti-
vated YF17D virus stimulate an identical response clearly 
shows that viral replication is not required for the induction 
of adaptive immunity. Importantly, we show by gene array 
that most of the transcriptional nodes involved in the re-
sponse to YF17D in vivo that were identifi  ed with the Mon-
treal cohort (  Fig. 2  ) are also induced in the Lausanne cohort, 
as well as in the in vitro MIMIC system (Table S3), leading 
to the mobilization of several of their downstream transcrip-
tional targets. Specifi  cally, we found that immunization with 
YF17D elicits the induction of IRF1, IRF7, IRF8, STAT1, 
and FOXO3a in all three datasets, all of which are master-
switch genes required for the coordination of an effi   cient and 
protective immune response. Moreover, ICA followed by 
gene set enrichment (Table S4, available at http://www.jem
.org/cgi/content/full/jem.20082292/DC1) has revealed a sig-
nifi  cant enrichment of genes induced by IFNs and viruses 
among the three datasets, namely those from Montreal, Laus-
anne, and VaxDesign  ’  s MIMIC system. 
  Our results highlight the critical role of innate immunity 
in the elicitation of the multilineage and broad immune re-
sponses observed herein, and demonstrate the complexity of 
the innate immune response that is generated upon vaccina-
tion with YF17D. Indeed, several eff  ector molecules of the 
innate immune response, including complement, IFNs, the 
infl  ammasome, and several eff  ector cells of innate immunity 
(i.e., macrophages, NK cells, and DCs, the latter being most 
likely the producers of type I IFNs [  55  ]), are involved in this 
early response (day 3 and 7). Control of viral replication JEM VOL. 205, December 22, 2008 
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Vivo 15 medium (Lonza), with YF17D, and harvesting the culture supernatants 
when severe histopathology could be observed (6  –  7 d). The virus particles 
were concentrated using Centricon Plus-20 columns (100 kD cutoff  ; Milli-
pore). Viral stocks were titrated on Vero cells by lysis plaque assay. The virus 
was either heat-inactivated by incubation at 65  °  C for 1 h, or UV-inactivated 
at a dose of 0.72 J/cm  2   in a Stratalinker 1800 (Stratagene). Inactivated 
YF17D was tested by plaque assay to ensure total inactivation. 
  Immature DCs were generated by culturing monocytes for 6 d in the 
presence of 100 ng/ml GM-CSF (R  &  D Systems) and 25 ng/ml IL-4 (R  &  D 
Systems). The cells were then incubated with live, UV-inactivated or heat-
inactivated YF17D, at a multiplicity of infection of 10. After 24 and 48 h, 
supernatants were collected and analyzed using an IL-1     ELISA kit (BD). 
  Proliferation and cytokine secretion assays.     PBMCs from vaccinated 
volunteers were labeled with CFSE (Invitrogen), as previously described 
(  64  ). 2 million cells were incubated in polypropylene snap-cap tubes (Fal-
con) in the presence of YF17D-derived peptide pools (Fig. S6 a) at a fi  nal 
concentration of 2   μ  g/ml/peptide, SEB (50 ng/ml; Toxin Technology) or 
nothing (nonstimulated; NS). After 24 h of incubation at 37  °  C/5% CO  2  , 
120   μ  l of supernatant was withdrawn from each tube and frozen at     80  °  C 
for subsequent cytokine analysis. The same volume of fresh medium was re-
placed in each tube, and 5 d later (6 d total incubation), the cells were har-
vested and stained with anti-CD3, -CD4, and -CD8 antibodies (BD). The 
cells were collected on a BD LSRII fl  ow cytometer and the results were ana-
lyzed using the BD FACSDiva software. The BD Th1/Th2 CBA array (BD) 
was used to measure levels of IL-2, IL-4, IL-5, IL-10, IFN-    , and TNF in 
PBMCs supernatants, as suggested by the manufacturer. 
  Flow cytometric analysis of IFN-    /IL-2  –  producing activated CD4 
T cells.     To assess the cytokine production ability of YF17D-specifi  c helper 
T cells, 2 million PBMCs from vaccinated subjects (day 14 and 28) were 
stimulated for 6 h with YF17D-derived peptide pools, in the presence of 
Brefeldin A (Sigma-Aldrich), and then stained with anti-CD8 and -CD4 
antibodies. They were then permeabilized and stained with anti-CD154, 
IL-2, and IFN-     (BD). 
  To determine the T helper phenotype of long-term, vaccine-specifi  c 
CD4  +   T cells, 2 million PBMCs were stimulated for 6 d with YF17D pep-
tide pools, and subsequently restimulated with the same pools for 12 h, in the 
presence of Brefeldin A. Non-restimulated cells were used as controls. The 
cells were then stained with anti-CD3, -CD4, -CD8, -CD45RA, -CCR7, 
-CCR4, -CXCR3, and -CCR6 antibodies (BD). After permeabilization, 
they were stained for intracellular CD154 and fi  xed. 
  The MIMIC co-culture system.     PBMCs used in the assays were acquired 
from normal healthy donors enrolled in a VaxDesign Corporation apheresis 
study program (protocol CRRI 0906009). Blood collections were per-
formed at Florida  ’  s Blood Centers (Orlando, FL) using standard techniques. 
The enriched leukocytes were isolated and cryopreserved. Human DCs 
were prepared as described above. After 5 d of culture with IL-4 and GM-
CSF, the DCs were infected with a 1:100 dilution of the live-attenuated 
YF-VAX vaccine. After 24 h, 5% human AB serum was added to the media 
to quench the infection. Alternatively, some of the DCs were pulsed with a 
1:100 dilution of YF-VAX (YF) that had been UV-inactivated. On the sixth 
day, all DCs were matured with an overnight treatment of 25 ng/ml TNF-     
(R  &  D Systems). 
  CD4  +   T cell stimulation assay.     Frozen stocks of autologous PBMCs 
were used as a source of lymphocytes. Purifi  ed CD4  +   T cells were co-cul-
tured with untreated or YF17D-pulsed DCs at a ratio of 60:1 for 14 d; 
thereafter, the activated lymphocytes were harvested and evaluated for eff  ec-
tor activity using autologous DCs as APCs. The T cells and APCs were co-
cultured for 7 h, stained with CD4 antibody, permeabilized, and labeled 
intracellularly with anti  –  IFN-    ,   –  IL-5,   –  IL-13, and -CD154 antibodies. 
  Multiplex cytokine analysis.     At the time the lymphocytes were harvested 
from DC/T cell co-cultures, the supernatants were also collected and stored 
  Gene array analysis of whole-blood and VaxDesign samples.     Whole-
blood total RNA was purifi  ed from PaxGene tubes using RNA extraction 
kits (QIAGEN). Quantifi  cation was performed using a spectrophotometer 
(NanoDrop Technologies) and RNA quality was assessed using the Ex-
perion automated electrophoresis system (Bio-Rad Laboratories). Total 
RNA was then amplifi  ed and labeled using the Illumina TotalPrep RNA 
Amplifi  cation kit, which is based on the Eberwine amplifi  cation protocol 
(  58  ). This protocol involves a fi  rst cDNA synthesis step followed by in vitro 
transcription for cRNA synthesis. The biotinylated cRNA was hybridized 
onto Illumina Human RefSeq-8 BeadChips v2 (Montreal and Lausanne 
samples) or v3 (VaxDesign samples) at 58  °  C for 20 h and quantifi  ed using Il-
lumina BeadStation 500GX scanner and Illumina BeadStudio v3 software. 
  Illumina probe data were exported from BeadStudio as raw data and 
screened for quality. Samples failing chip visual inspection and control ex-
amination were removed. Gene expression data were analyzed using Bio-
conductor (  59  ), an open-source software library for the analyses of genomic 
database on R, which is a language and environment for statistical comput-
ing and graphics (www.r-project.org). The R software package was used to 
fi  rst fi  lter out probes with intensities below background in all samples, and 
then to minimum replace (a surrogate replacement policy) values below 
background using the mean background value of the built-in Illumina probe 
controls as an alternative to background subtraction (which may introduce 
negative values) to reduce   “  overinfl  ated  ”   expression ratios determined in 
subsequent steps, and fi  nally quantile normalize the probe intensities. The 
resulting matrix showing probes as rows and samples as columns was log  2   
transformed and used as input for linear modeling using BioConductor Lin-
ear models for microarray analysis (LIMMA [  60  ]). The LIMMA package 
(  61  ) was used to identify diff  erentially expressed genes (pFDR   <  0.05; fold 
change greater than     1.3 or   >  1.3) at days 3, 7, 10, 14, 28, and 60, compared 
with day 0 for the Montreal samples, at days 3 and 7 compared with day 0 
for the Lausanne samples, and at days 3 and 7 compared with the respective 
control for the VaxDesign samples. Our microarray data are available through 
the National Center for Biotechnology Information Gene Expression Om-
nibus (GEO) under series accession no. GSE13699. 
  qPCR validation.     Changes in gene expression observed by microarray 
analyses were verifi  ed by qPCR. The expression of 43 genes, which were 
chosen according to our microarray results and to biomedical literature, was 
analyzed on samples obtained at day 0 and 7 after vaccination from the Mon-
treal and Lausanne cohorts. To further validate our microarray data, we also 
performed qPCR analysis on RNA samples (day 0 and 7) from 10 YF17D-
vaccinated volunteers enrolled in another vaccination trial conducted by the 
Emory Vaccine Center in Atlanta, GA (a gift from B. Pulendran). qPCR 
analysis was performed at the genomics platform of the Institute for Research 
in Immunology and Cancer (Montreal), as previously described (  62  ). 
  Identifi  cation of transcription factors and curated gene sets.     Tran-
scription factors were identifi  ed using ICA and gene set enrichment as de-
scribed in Teschendorff   et al. (  63  ). ICA was performed on the expression 
profi  les of the whole-blood and ex vivo model gene arrays (Montreal, Laus-
anne, and VaxDesign) on each day individually, as well as on the whole da-
tasets from each study. The CRAN package fastICA (v1.1-9) was used to 
carry out the ICA. Genes in each component were chosen for enrichment 
by selecting genes with loads below the 2.fi  fth percentile or above the 97.
fi  fth percentile. Gene set enrichment was done on the C2   “  curated gene 
sets  ”   and C3   “  motif gene sets  ”   collections of MsigDB. The resulting P values 
were Benjamini-Hochberg adjusted to keep the false discovery rates within 
each component   <  5%. Results annotated with unknown transcription fac-
tors that were discarded. Additionally, at least one gene in the gene sets used 
for enrichment had to be diff  erentially expressed (see Gene array analysis of 
whole blood and VaxDesign samples) on at least one of the available time 
points up to day 14. 
  In vitro infection of immature DCs with YF17D.     Stocks of live 
YF17D virus were prepared in our laboratory by infecting Vero cell mono-
layers grown in DME medium (Sigma-Aldrich) supplemented with 10% X-3130 IMMUNE RESPONSE TO THE YELLOW FEVER VACCINE 17D   | Gaucher et al. 
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